Literature DB >> 16751806

Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland.

A P L Smith1, M Henze, J A Lee, K G Osborn, J M Keck, D Tedesco, D M Bortner, M P Rosenberg, S I Reed.   

Abstract

Deregulation of cyclin E expression and/or high levels have been reported in a variety of tumors and have been used as indicators of poor prognosis. Although the role that cyclin E plays in tumorigenesis remains unclear, there is evidence that it confers genomic instability when deregulated in cultured cells. Here we show that deregulated expression of a hyperstable allele of cyclin E in mice heterozygous for p53 synergistically increases mammary tumorigenesis more than that in mice carrying either of these markers individually. Most tumors and tumor-derived cell lines demonstrated loss of p53 heterozygosity. Furthermore, this tumor susceptibility is related to the number of times the transgene is induced indicating that it is directly attributable to the expression of the cyclin E transgene. An indirect assay indicates that loss of p53 function is an early event occurring in the mammary epithelia of midlactation mammary glands in which cyclin E is deregulated long before evidence of malignancy. These data support the hypothesis that deregulated expression of cyclin E stimulates p53 loss of heterozygosity by promoting genomic instability and provides specific evidence for this in vivo. Cyclin E deregulation and p53 loss are characteristics often observed in human breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751806     DOI: 10.1038/sj.onc.1209713

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Judith Schütte; Marijke N Boersma; Robert L Sutherland; Jason S Carroll; Elizabeth A Musgrove
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

Review 2.  Signaling pathways that control cell proliferation.

Authors:  Robert J Duronio; Yue Xiong
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-03-01       Impact factor: 10.005

3.  Insertional mutagenesis using the Sleeping Beauty transposon system identifies drivers of erythroleukemia in mice.

Authors:  Keith R Loeb; Bridget T Hughes; Brian M Fissel; Nyka J Osteen; Sue E Knoblaugh; Jonathan E Grim; Luke J Drury; Aaron Sarver; Adam J Dupuy; Bruce E Clurman
Journal:  Sci Rep       Date:  2019-04-02       Impact factor: 4.379

4.  An integrated view of cyclin E function and regulation.

Authors:  Ka Tat Siu; Marsha Rich Rosner; Alex C Minella
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

5.  The PP2A-B56 Phosphatase Opposes Cyclin E Autocatalytic Degradation via Site-Specific Dephosphorylation.

Authors:  Ryan J Davis; Jherek Swanger; Bridget T Hughes; Bruce E Clurman
Journal:  Mol Cell Biol       Date:  2017-03-31       Impact factor: 4.272

6.  Hypoxia-inducible factor 1 is activated by dysregulated cyclin E during mammary epithelial morphogenesis.

Authors:  Tanushri Sengupta; Gathi Abraham; Yanfei Xu; Bruce E Clurman; Alex C Minella
Journal:  Mol Cell Biol       Date:  2011-07-11       Impact factor: 4.272

Review 7.  The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation.

Authors:  K M Crusio; B King; L B Reavie; I Aifantis
Journal:  Oncogene       Date:  2010-06-14       Impact factor: 9.867

8.  Reduced spermatogonial proliferation and decreased fertility in mice overexpressing cyclin E in spermatogonia.

Authors:  Vasco Liberal; Maria P De Miguel; Martha Henze; Manuel Nistal; Steven I Reed
Journal:  Cell Cycle       Date:  2010-10-04       Impact factor: 4.534

9.  Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Authors:  Alison M Karst; Paul M Jones; Natalie Vena; Azra H Ligon; Joyce F Liu; Michelle S Hirsch; Dariush Etemadmoghadam; David D L Bowtell; Ronny Drapkin
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

10.  Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.

Authors:  James W Purcell; Jefferson Davis; Mamatha Reddy; Shamra Martin; Kimberly Samayoa; Hung Vo; Karen Thomsen; Peter Bean; Wen Lin Kuo; Safiyyah Ziyad; Jessica Billig; Heidi S Feiler; Joe W Gray; Kenneth W Wood; Sylvaine Cases
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.